Total Payments
$4,619
2024 Payments
$1,015
Companies
41
Transactions
262
Medicare Patients
5,218
Medicare Billing
$2.5M
Payment Breakdown by Category
Food & Beverage$4,387 (95.0%)
Education$231.35 (5.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,387 | 257 | 95.0% |
| Education | $231.35 | 5 | 5.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $639.87 | 53 | $0 (2024) |
| Sirtex Medical Inc | $392.78 | 9 | $0 (2024) |
| Merck Sharp & Dohme LLC | $375.90 | 24 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $357.47 | 26 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $307.88 | 10 | $0 (2023) |
| Daiichi Sankyo Inc. | $222.03 | 10 | $0 (2024) |
| Mirati Therapeutics, Inc. | $217.74 | 12 | $0 (2024) |
| Amgen Inc. | $200.88 | 12 | $0 (2023) |
| ARRAY BIOPHARMA INC | $171.14 | 10 | $0 (2024) |
| Exelixis Inc. | $153.47 | 9 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,015 | 52 | E.R. Squibb & Sons, L.L.C. ($196.59) |
| 2023 | $784.62 | 52 | E.R. Squibb & Sons, L.L.C. ($157.42) |
| 2022 | $516.35 | 29 | Bayer HealthCare Pharmaceuticals Inc. ($92.57) |
| 2021 | $354.02 | 21 | Novartis Pharmaceuticals Corporation ($94.94) |
| 2020 | $67.84 | 5 | E.R. Squibb & Sons, L.L.C. ($28.61) |
| 2019 | $377.71 | 29 | Novartis Pharmaceuticals Corporation ($141.22) |
| 2018 | $798.41 | 50 | Sirtex Medical Inc ($112.35) |
| 2017 | $705.17 | 24 | Sirtex Medical Inc ($176.13) |
All Payment Transactions
262 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | SEAGEN INC. | — | Education | In-kind items and services | $98.65 | General |
| 12/19/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $23.05 | General |
| Category: Oncology | ||||||
| 12/12/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $17.60 | General |
| Category: Oncology | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $17.27 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $17.19 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $6.30 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $21.83 | General |
| Category: Hematology/Oncology | ||||||
| 10/31/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $18.64 | General |
| Category: Oncology | ||||||
| 10/30/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Food and Beverage | In-kind items and services | $15.10 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $23.78 | General |
| Category: ONCOLOGY | ||||||
| 10/18/2024 | BeiGene USA, Inc. | TEVIMBRA (Drug) | Food and Beverage | In-kind items and services | $18.19 | General |
| Category: Oncology | ||||||
| 10/10/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $19.43 | General |
| Category: ONCOLOGY | ||||||
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $13.85 | General |
| Category: Oncology | ||||||
| 09/26/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $16.54 | General |
| Category: Oncology | ||||||
| 09/19/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), TUKYSA | Food and Beverage | In-kind items and services | $17.70 | General |
| Category: ONCOLOGY | ||||||
| 09/12/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $19.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 09/12/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Food and Beverage | In-kind items and services | $18.70 | General |
| Category: ONCOLOGY | ||||||
| 09/05/2024 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $20.25 | General |
| Category: Oncology | ||||||
| 09/05/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $19.40 | General |
| Category: ONCOLOGY | ||||||
| 09/05/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $7.21 | General |
| Category: Oncology | ||||||
| 08/08/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Food and Beverage | In-kind items and services | $19.00 | General |
| Category: ONCOLOGY | ||||||
| 08/01/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $18.70 | General |
| Category: Hematology/Oncology | ||||||
| 07/30/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: Oncology | ||||||
| 07/26/2024 | Genentech USA, Inc. | Tecentriq (Biological) | Food and Beverage | In-kind items and services | $18.19 | General |
| Category: BioOncology | ||||||
| 07/25/2024 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $19.00 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 962 | 4,696 | $2.4M | $485,836 |
| 2022 | 21 | 1,694 | 9,028 | $2.6M | $682,955 |
| 2021 | 24 | 1,345 | 15,212 | $1.7M | $617,676 |
| 2020 | 19 | 1,217 | 5,404 | $1.7M | $717,459 |
Total Patients
5,218
Total Services
34,340
Medicare Billing
$2.5M
Procedure Codes
76
All Medicare Procedures & Services
76 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | Office | 2023 | 38 | 2,173 | $1.8M | $231,406 | 12.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 179 | 825 | $248,048 | $123,032 | 49.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 209 | 601 | $143,902 | $62,527 | 43.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 143 | 329 | $50,608 | $22,118 | 43.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 101 | 117 | $49,428 | $16,998 | 34.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 94 | 144 | $31,911 | $14,341 | 44.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 45 | 45 | $20,310 | $7,865 | 38.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 39 | 43 | $7,909 | $2,911 | 36.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 46 | 214 | $15,774 | $2,596 | 16.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 35 | 142 | $4,655 | $989.30 | 21.3% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 13 | 19 | $1,965 | $786.86 | 40.0% |
| 85027 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2023 | 20 | 44 | $1,395 | $266.28 | 19.1% |
| Q5111 | Injection, pegfilgrastim-cbqv, biosimilar, (udenyca), 0.5 mg | Office | 2022 | 58 | 2,763 | $1.8M | $339,188 | 19.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 216 | 920 | $276,000 | $141,386 | 51.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 279 | 773 | $193,250 | $82,271 | 42.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 124 | 141 | $60,630 | $23,904 | 39.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 155 | 344 | $51,600 | $20,998 | 40.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 23 | 109 | $43,600 | $13,329 | 30.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 69 | 69 | $33,810 | $13,018 | 38.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 348 | 1,427 | $42,810 | $10,644 | 24.9% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2022 | 23 | 64 | $10,240 | $10,214 | 99.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 62 | 94 | $18,800 | $8,258 | 43.9% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2022 | 17 | 152 | $15,200 | $4,299 | 28.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 26 | 32 | $9,600 | $3,714 | 38.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 67 | 294 | $14,700 | $3,520 | 23.9% |
About Dr. Tracy Proverbs-Singh, M.D
Dr. Tracy Proverbs-Singh, M.D is a Hematology healthcare provider based in Hackensack, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/24/2009. The National Provider Identifier (NPI) number assigned to this provider is 1730321662.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Tracy Proverbs-Singh, M.D has received a total of $4,619 in payments from pharmaceutical and medical device companies, with $1,015 received in 2024. These payments were reported across 262 transactions from 41 companies. The most common payment nature is "Food and Beverage" ($4,387).
As a Medicare-enrolled provider, Proverbs-Singh has provided services to 5,218 Medicare beneficiaries, totaling 34,340 services with total Medicare billing of $2.5M. Data is available for 4 years (2020–2023), covering 76 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Medical Oncology
- Location Hackensack, NJ
- Active Since 03/24/2009
- Last Updated 01/26/2022
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1730321662
Products in Payments
- OPDIVO (Biological) $607.69
- SIR-Spheres Microspheres (Device) $392.78
- KEYTRUDA (Biological) $346.71
- Stivarga (Drug) $307.88
- KRAZATI (Drug) $217.74
- BRAFTOVI (Drug) $188.35
- Enhertu (Drug) $143.21
- DARZALEX (Biological) $124.17
- GILOTRIF (Drug) $101.43
- Neulasta (Biological) $95.30
- CABOMETYX (Drug) $90.13
- MEKINIST (Drug) $89.86
- LONSURF (Drug) $76.99
- Lenvima (Drug) $72.50
- ZENPEP (Drug) $69.97
- Cabometyx (Drug) $63.34
- PROMACTA (Drug) $62.75
- TASIGNA (Drug) $58.22
- CYRAMZA (Drug) $56.55
- LUMAKRAS (Drug) $50.45
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology Doctors in Hackensack
Dr. James Mccloskey, M.d, M.D
Hematology — Payments: $2.8M
Hematology $2.8M
Dr. Jamie Koprivnikar, M.d, M.D
Hematology — Payments: $1.5M
Hematology $1.5M
Dr. Andrew Pecora, Md, MD
Hematology — Payments: $1.4M
Hematology $1.4M
Dr. David Vesole, Md, MD
Hematology — Payments: $1.1M
Hematology $1.1M
Dr. Lori Leslie, M.d, M.D
Hematology — Payments: $669,511
Hematology $669,511
Dr. Robert Alter, Md, MD
Hematology — Payments: $539,884
Hematology $539,884